# Ixazomib + Pomalidomide + Dexamethasone In MM

> **NCT04094961** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Omar Nadeem, MD** · enrollment: 52 (actual)

## Conditions studied

- Multiple Myeloma
- Multiple Myeloma in Relapse

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04094961
- **Lead sponsor:** Omar Nadeem, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-18
- **Primary completion:** 2025-06-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094961, "Ixazomib + Pomalidomide + Dexamethasone In MM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04094961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*